132 related articles for article (PubMed ID: 3471982)
1. ["A-triple-V" in refractory or relapsed acute myelocytic leukemia].
Miyawaki S; Nemoto K; Wakamatsu R; Baba N; Yashiro K; Uchida S; Nakura M; Karasawa M; Takada M; Tanaka H
Rinsho Ketsueki; 1987 Jan; 28(1):34-9. PubMed ID: 3471982
[No Abstract] [Full Text] [Related]
2. ["AB-Triple V" therapy of relapsed or refractory acute myelogenous leukemia].
Asou N; Suzushima H; Hamasaki N; Goto J; Hidaka M; Akagi K; Kurisaki H; Sawatari T; Kawano F; Takatsuki K
Rinsho Ketsueki; 1989 Feb; 30(2):169-74. PubMed ID: 2746873
[TBL] [Abstract][Full Text] [Related]
3. ["A-Triple-V" treatment of relapsed or refractory acute leukemia].
Makino S; Araki Y; Tamura K; Seita M
Rinsho Ketsueki; 1988 Sep; 29(9):1394-8. PubMed ID: 3216510
[No Abstract] [Full Text] [Related]
4. [A study of B-triple V (behenoyl-ara C, etoposide, vincristine, vinblastine) in acute leukemia].
Kohsaki M; Nagai K; Kanamaru A; Takaku F; Kobayashi Y; Mizoguchi H; Akaboshi M; Tsuchiya J; Miyawaki S; Sawamura M
Rinsho Ketsueki; 1988 Apr; 29(4):527-33. PubMed ID: 3043041
[No Abstract] [Full Text] [Related]
5. ["B-triple V" therapy as a initial induction treatment of acute leukemias].
Yokomatsu Y; Sagawa H; Yamane T; Hiyoshi M; Sasaki A; Kishida T; Kojima K; Yoshikawa T; Sannomiya Y; Kawarabayashi K
Rinsho Ketsueki; 1987 Nov; 28(11):1935-40. PubMed ID: 3446866
[No Abstract] [Full Text] [Related]
6. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
8. [Chemotherapy of relapsed AML and ALL].
Nishikawa K
Rinsho Ketsueki; 1996 Aug; 37(8):647-50. PubMed ID: 8827871
[No Abstract] [Full Text] [Related]
9. [Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
Nagata K; Abe Y; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K
Gan To Kagaku Ryoho; 1994 Feb; 21(2):231-6. PubMed ID: 8311494
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of acute leukemia with "MB-triple V" therapy--a comparative study of "MB-triple V" therapy and B-triple V therapy].
Yamane T; Inoue T; Furukawa Y; Sasaki A; Kishida T; Park K; Im T; Tatsumi N
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3729-33. PubMed ID: 2596856
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed and refractory acute myeloid leukemia in adults.
Lazzarino M; Morra E; Alessandrino EP; Merante S; Bernasconi P; Bonfichi M; Caldera D; Bernasconi C
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():121-3. PubMed ID: 2653487
[No Abstract] [Full Text] [Related]
12. [Results of treating acute myeloid leukemia resistant to conventional chemotherapy with moderately large doses of cytarabine and etoposide].
Robak T; Krykowski E; Matusewicz W; Brodowski L; Hołub A; Drzewoski J
Pol Tyg Lek; 1988 Nov; 43(47):1508-11. PubMed ID: 3075284
[No Abstract] [Full Text] [Related]
13. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Feldman EJ; Brandwein J; Stone R; Kalaycio M; Moore J; O'Connor J; Wedel N; Roboz GJ; Miller C; Chopra R; Jurcic JC; Brown R; Ehmann WC; Schulman P; Frankel SR; De Angelo D; Scheinberg D
J Clin Oncol; 2005 Jun; 23(18):4110-6. PubMed ID: 15961759
[TBL] [Abstract][Full Text] [Related]
14. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
Lee SS; Lee JH; Lee JH; Kim DY; Kim SH; Lim SN; Lee YS; Seol M; Ryu SG; Kang YA; Jang S; Park CJ; Chi HS; Yun SC; Lee KH
Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
[TBL] [Abstract][Full Text] [Related]
15. [The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
Kawano F; Tejima Y; Tajima H; Lee SY; Shiozaki A; Nakai R; Chyosa M; Sawada T; Maeda Y; Mizokuni T
Rinsho Ketsueki; 1986 Mar; 27(3):315-20. PubMed ID: 3461178
[No Abstract] [Full Text] [Related]
16. Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia.
Willemze R; Fibbe WE; Zwaan FE
Neth J Med; 1983; 26(8):215-9. PubMed ID: 6580554
[No Abstract] [Full Text] [Related]
17. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Jang S; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
Leuk Res; 2006 Feb; 30(2):204-10. PubMed ID: 16055185
[TBL] [Abstract][Full Text] [Related]
18. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
19. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
